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 Recently, neutrophil gelatinase-associ-
ated lipocalin (NGAL) has been intro-
duced as a sensitive and early marker of 
acute kidney injury  [5] . NGAL in cirrhosis 
and chronic renal failure has not been in-
vestigated so far. We have therefore ana-
lyzed NGAL and GFR in patients with
 Dear Sir, 
 Renal dysfunction is a frequent and 
clinically relevant problem in patients 
with cirrhosis of the liver  [1] . While acute 
renal failure as in hepatorenal syndrome 
type 1 is characterized by a rapid increase 
of serum creatinine (Crea) concentration 
 [2] , chronic renal dysfunction may be dif-
ficult to detect. For determination of the 
glomerular filtration rate (GFR), the use of 
clearance techniques is the gold standard. 
These techniques, however, are cumber-
some and not suitable for clinical routine. 
Serum Crea is simple and easy to deter-
mine and therefore widely used per se or
in Crea-based formulae such as MDRD 
(Modification of Diet in Renal Disease for-
mula, using serum Crea, age and gender). 
Unfortunately, Crea is not a precise pa-
rameter of renal function in cirrhosis  [3] . 
The overestimation of GFR by serum Crea 
and Crea-based equations is striking, par-
ticularly in decompensated patients with 
cirrhosis and normal or slightly increased 
Crea. Clinically it seems most important 
to identify renal dysfunction in these pa-
tients at an early stage before development 
of a hepatorenal syndrome denoting a 
poor prognosis. Therefore, other serum 
parameters such as cystatin C have been 
proposed to reflect renal function in cir-
rhosis  [4] but have not been generally ac-
cepted yet.
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decompensated cirrhosis and normal or 
moderately increased Crea.
 Twenty-two patients with cirrhosis and 
ascites and stable Crea  ! 1.5 mg/dl had 
GFR measured by the  51 Cr-EDTA tech-
nique  [6] . The study was approved by
the regional ethics committee, registered 
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 Fig. 1. Serum Crea, estimated GFR as calculated by MDRD4 formula and serum NGAL 
in patients with cirrhosis and GFR  ! 50 or  1 50 ml/min. Only serum NGAL is signifi-
cantly different between both groups ( * ). 
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(NCT00115947) and inspected by the 
Danish Medicines Agency. Using sand-
wich-ELISA technique (Bioporto, Gen-
tofte, Denmark), NGAL in serum and 
urine was determined. A GFR of 50 ml/
min was considered as a clinically signifi-
cant cutoff point. Results are expressed as 
means and standard deviation. Statistical 
analyses were performed with unpaired t 
tests.
 GFR  ! 50 or  1 50 ml/min was found in 
6 and 16 patients, respectively (29  8 10 vs. 
69  8 15 ml/min; p  ! 0.01). These two 
groups exhibited Crea (1.1  8 0.3 vs. 0.8  8 
0.2 mg/dl; n.s.), estimated GFR (MDRD4) 
(65  8 17 vs. 106  8 34 ml/min; n.s.) and 
serum NGAL (136  8 61 vs. 50  8 15 ng/ml; 
p  ! 0.01) as shown in  figure 1 . Urinary 
NGAL was similar in both groups. Five of 
6 patients with GFR  ! 50 ml/min had 
NGAL  1 100 ng/ml. AUC analysis showed 
NGAL with a cutoff of 100 ng/ml superior 
(p  ! 0.05) to Crea (0.98; 0.96–1.00 vs. 0.79; 
0.66–0.92) in identifying patients with a 
GFR  ! 50 ml/min.
 These data in a small but well-charac-
terized group of patients indicate that se-
rum NGAL could be a sensitive novel 
marker of low GFR in cirrhosis. Further 
evaluation seems warranted.
 
